• Skip to main content
  • Skip to primary sidebar
  • Home
  • News
  • Events
  • Education
  • Interviews
    • Career spotlight
  • Opinion
    • Professional Dilemmas
    • Patient perspective
  • PIPcast
  • Jobs
  • Business Directory

Pharmacy in Practice

EDX/20/1154
Date of prep: December 2020

Prescribing information and
adverse events reporting

For healthcare professionals only

Drug chart confusion contributes to pulmonary embolism

15th October 2020 by PIP editor Leave a Comment

 

Crucial treatments missed in stroke aftercare could lead to fatal blood clots, says a new report from the Healthcare Safety Investigation Branch (HSIB).

 

HSIB examined the patient safety risks after looking at the case of a 78-year old woman who suffered a pulmonary embolism whilst recovering from a stroke in hospital.

 

Following her stroke, she was treated with ‘clot-busting’ drugs, known as thrombolysis, and had an initial assessment to determine whether she was at risk of venous thromboembolism (VTE). Due to her immobility, the patient’s risk of acquiring a DVT or pulmonary embolism (PE) was high. It was noted on her chart that she should be fitted with what is known as an intermittent pneumatic compression (IPC) device rather than receive anticoagulants to reduce her risk of VTE as recommended by NICE.

 

However, due to several factors, the device was never fitted and on day 19 of her rehabilitation in the hospital she was diagnosed with ‘pulmonary emboli with saddle embolism.’

 

She received treatment for the clots and eventually discharged 53 days after arriving at the Trust to continue her recovery at home.

 

Strokes are the fourth most common cause of death in the UK and around one in ten people die before they reach the hospital. HSIB’s report emphasised that if patients do survive then the assessment of care in wards and units is key to prevent any further risk to life.

 

HSIB’s investigation focused on what happens after thrombolysis treatment is given and how VTE risk is managed as patients recover. Early on, they identified issues such as a low rate of IPC’s being fitted despite their success in improving the survival rates of those who are not mobile after a stroke and their recommendation by NICE guidelines.

 

As the investigation progressed, they identified missed opportunities throughout the whole process of care.

 

There is a lack of a national, stroke-specific assessment for VTE that considers the patient’s specific circumstances or determines the level of risk the patient has of blood clots forming. Even if an assessment identifies IPC as a treatment, the case that HSIB examined reflected a wider picture of confusion over how the devices are recorded i.e. on the patient’s chart and who then is responsible for fitting.

 

HSIB’s findings also show that national guidelines don’t require a follow-up assessment or a check that the VTE preventative measure is in place.

 

As a result of the national investigation, HSIB made one recommendation to facilitate the development of a stroke-specific assessment, a system for the associated treatment to be recorded using a tool to ensure that the relevant information is documented and, importantly, reviewed.

 

Dr Stephen Drage, HSIB’s Director of Investigations and ICU consultant said:

 

“The time after a patient is admitted and treated for a stroke is incredibly precarious. It is important that any safety risks in the care process are mitigated to prevent life-threatening blood clots forming to give patients the best chance of making a full recovery.

 

“A number of barriers to the most effective aftercare emerged through our investigation and the safety issues impact not only all specialist units but any wards where stroke recovery takes place in the NHS. The recommendation we have made is aimed at ensuring that VTE risk is managed in a targeted way that ensures that patients are getting the right treatment at the right time.”

 

You can read the full report by clicking here. 

 

 

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Related

Next article  Second wave of pharmacies join vaccination effort in England

Filed Under: Featured, News Tagged With: Pulmonary embolism, Stroke

Register for our upcoming webinar and live Q&A

About PIP editor

Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.

Reader Interactions

Begin the discussion right here Cancel reply

Primary Sidebar

Categories

Follow Us

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Twitter

PIP business directory

Letters to the editor

Letters to the editor

Provisionally registered pharmacists should not have to sit the exam

Admiration for community pharmacy in Scotland

Pharmacy technicians could help reduce medication waste

Community pharmacy central to tackling hepatitis C

More letters to the editor here...

Blogs

💊 PIP live pharmacy blog

Winter stresses must not ‘destabilise’ general practice

What is it like to depend on medicine to treat endometriosis?

Opinion

Why is pharmacy not integral to government mass vaccination plans?

Pharmacy Covid-19 vaccination involvement is a ‘no-brainer’

The great patient medication returns debacle

CPD Challenges

💊 CPD Challenge: How well do you understand pulmonary embolisms?

💊 CPD Challenge: Prescribing and dispensing clozapine

💊 CPD Challenge: Oral anticoagulants – Dabigatran

More CPD challenges here...

© 2021 · About Pharmacy In Practice · Site mantained by Mike

This site is for healthcare professionals, please confirm you are a healthcare professional to continue.

YES

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Pharmacy In Practice uses cookies, by continuing to use this site we will assume you are ok with that Find out more.